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Abstract
The interaction between cis- and trans- RuCI2(DMSO)4 and human serum albumin have been investigated
through UV-Vis, circular dichroism, fluorescence spectroscopy and inductively couplet plasma atomic
emission spectroscopy (ICP(AES)) method Albumin can specifically bind mole of cis-isomer and 2 moles
of the trans-isomer RuCIz(DMSO)4 complex. The interaction of RuClz(DMSO)4 with HSA causes: a
conformational change with the loss of helical stability of protein; the strong quenching of the Trp 214
fluorescence indicating that the conformational change of the hydrophobic binding pocked in subdomain IIA
takes place; a local perturbation of the warfarin binding site and induce some conformational changes at
neighbour domains, a changing of the binding abilities towards heine.
Introduction
In recent years metal-based antitumor drugs have been playing a relevant role in antiblastic-chemotherapy,
especially cis-DDP is regarded as one of the most effective anticancer drugs used in clinics. Among non
platinum transition metal anticancer compounds, ruthenium complexes haveraised great interest. In a
relatively early stage, the antitumor properties of ruthenium (II) with dimethyl sulfoxide (DMSO) as ligand,
were reported, obviously selected for its neutrality and structural relation with cisplatin ].
Compared to cisplatin the ruthenium(II) complex is less toxic and can be administrated in a remarcably
higher maximum dose. Despite its octahedral geometry and the absence of amino ligands, cis-RuClz(DMSO)4
presented some interesting analogies with cis-PtClz(NH)z (cisplatin), that is neutrality ,two cis-chloride
ligands, high stability of 2+ oxidation state and high affinity for nitrogen donor ligands. In the later study,
also the trans-isomer of this dmso complex proved to posses a comparable activity, and striking at much
lower doses than the cis isomer [2]. Both isomers, cis-and trans-RuCl(DMSO)4 were shown to posses
antitumor and in particular, remarkable antimetastatic activity against some murine tumor models(P388
leukemia, platinum resistant P388, Lewis lung carcinoma, B 16 melanoma [2-4].
Moreover the ruthenium complexes had an overall less pronounced host toxicity than cisplatin.
Ruthenium(II) complexes interacts ,,in vitro" with DNA to form covalent bounds with the nucleobases,
especially guanine N715].
Studies of the toxicity and antitumor activity of cis- and trans RuCIz(DMSO)4 show a significantly higher
toxicity of trans isomer. In contrast, both complexes exhibit a significant antimetastatic activity, cis-
RuCI2(DMSO)4 reduces the number and weight of spontaneus lung metastases by 46% and 52% respectively.
The trans isomer is slightly more active than the cis one with an inhibition of 57% and 71% respectively. The
antimetastatic activity of cis-DDP is only slightly more pronounced than that oftrans-RuCl2(DMSO)4 [6].
The two complexes are very stable towards air oxidation in solution, and in both cases, in analogy to
cisplatin, the dissociation eguilibrium is inhibited by extracellular chloride concentration. The chloride
dissociation process that follows DMSO release is faster in the cis-isomer, due to the trans-effect of DMSO.
Owing to the higher number of free coordination positions and, in particular, to the lower steric hindrance,
the aquo-derivatives of trans-RuClz(DMSO)4 are more reactive than those of the cis-isomer. In this way, the
trans isomer is more capable of binding to biomolecules, and accordingly, much more cytotoxic than the cis-
form. The study of the interaction of the complexes with imidazole confirmed that trans isomer turns out to
be considerably more reactive then the cis isomer towards N-donor ligands [6].
To obtain an insight into the intravenously administered antitumor metal complexes, it is important to study
the interaction of these with plasma proteins, especially albumin., which plays a central role in the molecular
pharmacology of drugs used in the cancer chemotherapy.
Human serum albumin (HSA) interferes with certain anticancer agents, changing their biological activity and
clinical effectiveness [7].
HSA is a single-chain 66 kDa protein, which is largely m-helical, and. consists of three structurally
homologous domains, that assemble to form a heart- shaped molecule. Each domain is a product of two
subdomains, which are predominantly helical and extensively cross-linked by several disulphide bridges [8].
Its amino-acid sequence contains a total of 17 disulphide bridges, one free thiol (Cys 34) and a single
tryptophan (Trp 214). Albumin is known to bind and transport many ligands, including fatty acids, amino
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acids, steroids, metal ions, and a variety of pharmaceuticals [8,9]. The principal regions of ligand binding
sites of albumin are located in hydrophobic cavities in subdomains IIA and IIIA, which exhibit similar
chemistry. The binding locations have been determined crystallographically for several ligands [8]. The IIIA
subdomain is the most active in accommodating of many ligands, as for example, digitoxin, ibuprofen and
tryptophan. Aspirin show nearly equal distributions between binding sites located in IIA and III subdomains,
while warfarin occupies a single site in IIA [10].
Ligand biding to one domain (II or III) induces distinct conformational changes in the other domain, as both
subdomains share a common interface. Thus, the binding of particular drug molecule to serum albumin may
change considerably binding abilities ofliSA towards other molecules.
Previous studies [11,12] have demonstrated that the interactions of Ru(III) complexes with HSA causes
distinct variations in protein conformation including a considerable decrease of the helical structure and a
change ofliSA binding abilities towards other molecules.
In this work we have performed extended studies on the interaction of human serum albumin with Ru(II)
dimethylsulfoxide complexes
The effect between ruthenium complexes with albumin has been investigated through gel-filtration
chromatography, UV/visible, CD, fluorescence spectroscopy and ICP(AES) method.
MATERIALS AND METHODS
Materials
The human serum albumin was obtained from Fluka Chem.Co. Warfarin and Sephadex-25 were purchased
from Sigma. HSA concentration was determined by absorption spectrum, taking the absorbance of a
lmg/cm at 280 nm as 0.55 [13].
Hemin chloride was used as obtain from Serva. Its cnceqtration was evaluated spectrophotometrically in
0.01M NaOH, using absorption coefficient of 58.4mM" cm" at 385nm [13].
Cis-and trans- RuCI2(.IMSO)4 synthesized as described earlier [2] and was used in all experiments from a
freshly prepared 2xl0 -M aqueous solution.
In all the experiments a physiological buffer, pH 7.4 was used.
Complexes o.0albumin wit ruthenium (II) cqqnpound were prepared by incubati_q)q of the reaction mtures
for 48 h at 37 C; 48 h at37vC and 5 days at 4vC (7 days of incubation); 48 h at 37 C and 12 days at 4vC (14
days of incubation) in sterillized tubes.
Methods
Absorption and Difference Spectra were recorded on SPECORD M-42 spectrophotometers, and CD spectra
on a Jasco JK-600 spectropolarimeter. CD spectra were recorded over the range of 190-250 and 300-600 rim,
using 0.1 and 1.0 cm cuvettes respectively. Secondary structure composition were calculated by Microsoft
Dicroprot V2.4 program (by Gilbert Deleage, Institut de Biologie et Chemie des Proteines, Lyon, France).
Fluorescence measurements were carried out on an SLM AMINco SPF-500 spectrofluorimeter with the
excitation and emission wavelength set at 298 and 350 nm (HSA) and 335 and 378 nm (warfarin).
The assays of ruthenium bounded per mol of HSA were performed with a SPECTROMETER 3410
(Inductively Couplet Plasma-Atomic Emission Spectroscopy, ICP-AES). HSA was allowed to react with ten
fold molar excess of ruthenium complex for 14 days at pH 7.4.
The sample was than chromatographed on the Sephadex G-25 column (2x50 cm) equilibrated and eluted with
physiological buffer pH 7.4.
The ruthenium content in selection fraction was determined by the ICP method.
RESULTS AND DISCUSSION
Binding of Ru(ll) complexes to HSA
Fig.1 shows the binding of cis-and trans- RuCI2(DMSO)4 to HSA as a function of incubation time over a 14
days period. Binding of trans-isomer to HSA was the most effective one. When ruthenium(II) complexes
were incubated at 10-fold excess to HSA, the adduct Ru/protein was formed for both cis- and trans-Ru(II),
but the binding of trans isomer was the most effective case. Equilibrium was completed during 24h in the
case of trans isomer (2 mole per mol of HSA) and 48h in the case of cis-RuCIz(DMSO)4 (1 tool per mol of
HSA). Fig.1.
The essential difference between the two isomers is a kinetic one. In both cases, in analogy to cisplatin the
dissociation equilibrium is inhibited by extracellular chloride concentration. Upon dissociation in water,
trans-RuCl2(DMSO)4 releasees two DMSO molecules quicly (cis-isomer one DMSO molecule) and one C!
slowly. The higher number of free coordination positions and lower steric hindrance, causes,that the aquo-
derivatives oftrans-RuCl2(DMSO)4 are more reactive than those of the cis-isomer.
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Figure .The binding of ruthenium complexes to HSA
as a function of incubation time, over a 14 day period.
The ruthenium content of selected fractions were
determined usingICP(AES) method.
Figure 2. CD spectra in the visible
region of cis-Ru(II)-HSA(- -) and
trans-Ru(II)-HS.A(--) after 48h of
incubation at 37vC. MoI.CD units:
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Figure 3A.CD spectra of liSA incubated for Figure 3B.Quantitative analysis of the secondary
48h with cis-and trans- RuCI26(DMSO)4. structure changes of liSA and Ru(II)-modified
Concentration of HSA: 8xl0 M.Molar ratio HSA, determined by DICROPROT V2.4 program.
Ru/HSA, 2"1.
This difference was confirmed earlier by studing their interaction with simple model molecules,imidazole
[14].
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Insights into the overall geometry can be found by examining the CD spectra of the RuCIz(DMSO)4 HSA
complexes. Circular dichroism spectroscopy is a technique particularly suited to prove specific binding of
small chromophoric complexes to chiral macromolecules of high molecular weight.[15]. In the visible region
(Fig 2) characteristic CD bands are seen at 330-350nm nm for both isomers and around 450 nm for trans-
isomer, after 48h of the incubation at 37C with HSA and separation by means of gel-filtration
chromatography The spectra are characteristic ofthe formation of a specific adduct with the protein.
Structural properties of the HSA modified with cis- and trans-RuCl2(DMSO)4
In order to obtain information about the structural perturbation of HSA, the CD and fluorescence
measurements are performed (Fig.3 and 4).
10.
//HSA
Wavelength [nm]
Figure 4.Fluorescence spectral changes of HSA incubated for 48h at 37 C with cis- and trans-
RuCI2(DMSO)4 at a molar ratio Ru/protein of 2. Concentration ofHSA:4xl0SM. Excitation at 298nm.
The albumin structure is predominantly ct- helical, the number of helices in the structure is 28 [8]. CD spectra
of HSA exhibit two negative bands in the ultraviolet region at 209 and 220 nm characteristic of an a-helical
structure. (Fig.3A). The ruthenium(II) complexes binding results in protein secondary structural changes
from that of the a- helix 50% (free HSA) to 43% (cis-isomer) and 33% (trans-isomer), I]-sheet 26% (free
HSA) to 32% (cis-isomer and 40% (trans-isomer) Fig.3B. The observed spectral changes indicate a partial
unfolding of the protein structure and major alterations of the protein secondary structure from that of the
helix to 13-sheet conformation. Trans isomer comparison with cis seems to be sterically more favoured by a
specific protein binding sites. From these results it is apparent that interaction of both isomers of
ruthenium(ll) with HSA causes a conformational change of the protein, with the loss of helical stability, as
found for the platinum[16], ruthenium(Ill) [11,12] and rhodium complexes [17].
Tryptophan fluorescence is most frequently examined among the three intrinsic aromatic fluorescing
groups in HSA molecules to obtain information about conformational changes [18].
Figure 4 shows typical changes of fluorescence intensity of the reaction mixture in which cis and trans-
RuCIz(DMSO)4 complexes and HSA were incubated for 48h at 37C. When HSA is excited at 300-298 nm,
a fluorescence efficiency around 350 nm reflects changes in the microenwronment of tryptophan residue. The
relative fluorescence intencity of ruthenium-bound HSA decreased to about 55% (cis-Ru) and to about 36%
(trans- Ru), when compared to the native state, suggesting that the binding occurs at the tryptophan residue or
its proximity. No change of the fluorescence intensity was observed for the control HSA solution over an
incubation period. It is very probable that the bindings of cis-and trans- RuCI2(DMSO)4 result in tryptophan
exposure to a polar environment. Much more effective quenching is observed in the case of trans-isomer,
when the amount of ruthenium bound to protein reaches twice.
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The strong quenching of the Trp214 fluorescence clearly indicate that the conformation of the hydrophobic
binding pocket in subdomain IIA is significantly affected by the ruthenium binding. It may be due to cis-and
trans- RuCIz(DMSO)4 binding to His 242 or His 246 being close to Trp 214 in the domain IIA binding
pocket, and possibly the other His residues located near this region.
Influence of ruthenium (II) on the warfarin and hemin binding to HSA
To provide further information about ruthenium binding site, the binding of warfarin, a site marker, was
also investigated.
25-
rfarin HSA
arf arin-cis Ru (11) -HSA
/.." .’- .. "..\ warfarin-trans Ru(ll)-I
/..".,." ".,.
t" ............N ................. -. ’’
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Figure 5. Relative fluorescence changes of warfarin with ruthenium- treated HSA. Excitation at 335nm and
emission at 378 nm. Warfarin was incubated for lh at 37C with H,SA(m), cis-Ru(II)-HSA( and trans
Ru(II)-HSA(-_-_-_) at molar ratio 1:2 Concentrations ofHSA:4xl0"JM; warfarin:8xl0M.
The warfarin is one of the best characterised drug as far as the binding sites are concerned [19]. Its site is
located in subdomains IIA near Trp-214 10].
Warfarin has a weak fluorescence at 378 nm when excited at 335 nm, and the addition of HSA induced an
increase in fluorescence intensity when warfarin binds to a single site in the protein [20].
Fig.5 shows the relative fluorescence changes of warfarin with RuCI2(DMSO)4 treated HSA.
Cis- and trans- RuCI2(DMSO)4 complexes were obtained after 48h incubation at 37C.
The strong fluorescence decrease of warfarin bound to protein indicates the reduction in the warfarin binding
capacity at the primary binding site of HSA. It is very likely that ruthenium binding occurs at the Trp-214
residue or in its proximity within a warfarin site I, located in subdomains IIA. Warfarin and many other drugs
(aspirinR, 5-iodo-salicylic acid, triiodobenzoic acid) were found to bind preferentially in IIA domain.
The heme-albumin and bilirubin-albumin complexes appears as an intermediate in the plasma heme and
bilirubin degradation processes. Earlier studies on heme-HSA interactions have shown that the protein posses
only one strong binding site for heme molecules although some weaker sites have been also proposed
[21,22]. The comparative study of the heme interaction with whole HSA as well as its three recombinant
domains [23] has indicated that primarys binding site is located in HSA-domain and additinal secondary
binding sites is placsd in in the HSA-domain II. The results shown in Fig.6 clearly indicate that cis-and
trans- RuCI2(DMSO)4 complexes bound to HSA modifies only insignificant the primary heme binding site.
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Figure 7. Effect of cis- and trans RuCIz(DMSO)4-HSA on the visible CD spectrum of HAS hemin complex"
hemin-HSA(_); hemin-cis Ru(II)-HSA(-- -); MolCD units: [Mcm].
When only the strongest binding sites are occupied, the characteristic CD signal of the heme with native
albumin appears. The method is based on the observation that an optical activity arises from dissymmetry in
the ligand induced by its binding to the protein, since the free ligand has either no asymmetric center.Hemin
is an optically inactive molecule, however, the strong interactions with protein induced chirality and its
intramolecular transition could be observed in the CD spectra.
The changes in the protein conformation within the hemin binding region indicates that cis-and trans-
RuCIz(DMSO)4 binding can induce some conformational changes at neighbour domains.
Conclusions
The interaction of anticancer drugs with blood constituents, particularly with serum albumin may have a
major influence on drug pharmacology and efficacy. [7]
As it was already shown [24,25] about 80% of platinum and ruthenium complexes in the blood plasma is
bound to serum proteins (primary albumin). Thus, it is important to understand the effect of this binding on
the structure of the protein and interactions with other biologically relevant ligands (e.g. drugs).
The results presented above clearly indicate that albumin can specifically bind mole of cis-isomer and 2
moles of the trans-isomer RuCI2(DMSO)4 complex according to ICP(AES) method.. The interaction of
RuCIz(DMSO)4 with HSA causes: a conformational change with the loss of helical stability of protein; the
strong quenching of the Trp 214 fluorescence indicating that the conformational change of the hydrophobic
binding pocked in subdomain IIA takes place; a local perturbation of the warfarin binding site. and induce
some conformational changes at neighbour domains, a changing of the binding abilities towards heme.
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